Novabay Pharmaceuticals ( (NBY) ) has released its Q3 earnings. Here is a breakdown of the information Novabay Pharmaceuticals presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NovaBay Pharmaceuticals, Inc. is a Delaware-based company primarily engaged in the development and sale of wound care products, with a focus on manufacturing and exporting to China. Recently, the company has divested its eyecare and skincare businesses, including the sale of its primary trademarks.
In its latest earnings report, NovaBay Pharmaceuticals highlighted a significant shift in its financial landscape. The company reported a net income of $4.455 million for the nine months ended September 30, 2025, compared to a net loss of $6.011 million in the same period of 2024. This turnaround was largely attributed to income from discontinued operations following the divestiture of its eyecare and skincare businesses.
Key financial metrics from the report include a gross profit of $42,000 on net product revenue of $521,000, alongside operating expenses totaling $6.479 million. The company also noted a significant reduction in current liabilities from $2.843 million at the end of 2024 to $1.448 million by September 2025. Despite these improvements, the company continues to face operating losses from its ongoing operations.
Looking ahead, NovaBay Pharmaceuticals is exploring new strategic directions, including potential opportunities in emerging financial infrastructure and blockchain-based markets. Management remains optimistic about the company’s ability to meet its operating expenses through November 2026, supported by recent capital raising activities and a focus on enhancing long-term shareholder value.